Skip to content
Open access

Cardiometabolic Protein Profile Changes During Gender-Affirming Hormone Therapy: A Prospective Clinical Study.

Oct 2026 · Clinical Endocrinology · 0 citations · 47 references
Medicine

TL;DR

T- and E2-based GAHT were associated with opposite directional changes in cardiometabolic protein profiles, and complement factor H and B, 3, 4b, 9, C-reactive protein, IGHA1, and afamin were higher in GAHT-ongoing TF individuals at baseline compared to GAHT-naïve TF individuals at 1 year.

Abstract

Objective

Cardiovascular disease (CVD) risk is elevated in transgender individuals during gender-affirming hormone therapy (GAHT) with expected different mechanisms between T- and E2-based GAHT. We investigated prospective changes in cardiometabolic proteins relating to complement, inflammation, and transport during GAHT.

Design

Prospective clinical study with assessment at baseline and after 1 year of GAHT. PATIENTS The main study population comprised 55 GAHT-naïve individuals (34 TM, 21 TF). An additional 35 GAHT-ongoing individuals (26 TM, 9 TF) were included as a cross-sectional comparison group at baseline.

Measurements

19 cardiometabolic proteins relating to atherosclerotic and thrombotic processes were analysed using targeted proteomics. Body composition was assessed by dual-energy X-ray absorptiometry.

Results

In GAHT-naïve TM individuals, the mean age at baseline was 27 years and median BMI was 26.5 (22.3-28.9) kg/m2. Following T-based GAHT, complement factor H and B, 3, 4b, and transport proteins (sex hormone-binding globulin, ceruloplasmin, corticosteroid-binding globulin, vitamin D-binding protein, vitronectin, and afamin) decreased, and transthyretin increased. In GAHT-naïve TF individuals, the mean age at baseline was 27 years and median BMI was 21.5 (20.3-23.6) kg/m2. Following E2-based GAHT, complement factor H and B, 3, 4b, 9, C-reactive protein, immunoglobulin heavy constant alpha 1 (IGHA1), and transport proteins increased. In cross-sectional analyses, complement factor H and B, 3, 4b, 9, C-reactive protein, IGHA1, and afamin were higher in GAHT-ongoing TF individuals at baseline compared to GAHT-naïve TF individuals at 1 year.

Conclusion

T- and E2-based GAHT were associated with opposite directional changes in cardiometabolic protein profiles. TRIAL REGISTRATION ClinicalTrials. gov (Identifier: NCT04254354, NCT05169762).

Read PDF

Similar papers

Open access Sep 2026

Cardiometabolic and atherosclerotic cardiovascular disease outcomes associated with tirzepatide: insights from a 1-year multicenter observational study

Reductions in estimated 10-year ASCVD risk were observed among individuals achieving at least 10% TBWL, supporting greater weight loss as an important marker of cardiovascular risk improvement.

Rene de J Rivera Gutierrez, Regina Castaneda, Alfredo Verastegui et al. · 0 citations
Open access Sep 2026

Adiposity, Body Composition, and Cardiometabolic Outcomes in Women with and Without Gestational Diabetes

Aims: Gestational diabetes mellitus (GDM) is associated with increased long-term cardiometabolic risk. The value of body composition measures in predicting adverse cardiometabolic outcomes after GDM remains uncertain. Methods: In this prospective observational study, 757 women (300 controls and 457 with GDM in their in...

M. Charakida, C. G. Fernández, T. Mansukhani et al. · 0 citations
Review Open access Sep 2026

Hormonal target validation based on biochemical shifts in gender-affirming hormone therapy.

The innate sexual dimorphism of biochemical parameters might provide a framework for GAHT target validation and significantly different hormonal profiles can be seen in people depending on the biochemical shift experienced during GAHT.

Jeroen Vervalcke, L. Marinelli, D. Glintborg et al. · 0 citations
Review Open access Oct 2026

Cardiometabolic diseases in transgender populations

The number of people seeking gender-affirming medical care and gender-affirming hormone therapy (GAHT) is increasing. As sex steroids shape cardiometabolic physiology, GAHT is expected to meaningfully alter cardiometabolic risk. The aim of this review was to systematically determine and narratively synthesize evidence...

Mattia Fienga, U. Tietge · 0 citations
Open access Sep 2026

Body fat distribution, lipid profile and cardiometabolic risk factors in perimenopause

Background: Body fat correlates with increased risks of metabolic and cardiovascular diseases, Young women are at a heightened risk for metabolic syndrome linked to dyslipidemia, which contributes to atherosclerosis. Objective: The aimed of study is correlation between body fat distribution, lipid profiles, and cardiom...

Rosdiana Mus, Elpira Asmin, Ingrid A. Hutagalung et al. · 0 citations
Open access Sep 2026

Effects of Glucoerb® and Epavin® on Cardiometabolic Profile in Adults with Overweight or Obesity: A Three-Month Real-World Study

Background/Objectives: Overweight and obesity are major drivers of cardiometabolic dysfunction and increase the risk of type 2 diabetes (T2DM)and cardiovascular disease. Although lifestyle intervention remains the cornerstone of treatment, complementary strategies may provide additional benefits. The effects of Glucoer...

V. Maggio, Francesca Vaccaro, Elena Muratore et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.